This is the login page for PHARMA JAPAN WEB subscribers. PHARMA JAPAN WEB offers excerpts of some articles for free, but paid subscription is required to read full articles.

Today's Headlines RSS

REGULATORY

LDP Weighs Clinical Development Infrastructure Utilizing Patient Registry

The ruling Liberal Democratic Party (LDP) is considering including a project to forge a clinical development platform using a patient registry in the government’s economic growth strategy to be updated ... > Read full story
REGULATORY
MHLW Looking into Drug Maker Payments to PAFSC Members: Shiozaki (Apr.24)
BUSINESS
Astellas Sees 59% Rise in FY2014 Operating Profit (Apr.24)
REGULATORY
Council on Unapproved Drugs to Issue Development Requests Immediately In Cases of Unanimous Approval by Working Groups (Apr.24)
REGULATORY
MHLW Orders Revision of Package Inserts for Plavix (Apr.24)
ORGANIZATION
JPMA Preparing “Action Guidelines” to Ensure Greater Transparency (Apr.24)
> More Latest News

Photosmore

  
JPMA Preparing “Action Guidelines” to Ensure Greater Transparency (Apr.24)MHLW Official Jo Hints at Possible Move-Up of Generic Roadmap (Apr.23)Find Solid Candidates from Early Development Stage: MHLW’s Mori (Apr.23)
  
JPMA to Step Up Calls for Biowaivers Using IVIVC (Apr.21)Nicholas Grund to Come Back as Genzyme Japan President after 8 Months (Apr.20)Takeda’s iPS Cell Deal Potential Game Changer in Drug Research (Apr.20)

News Categories

REGULATORY
   MHLW Looking into Drug Maker Payments to PAFSC Members: Shiozaki(Apr.24)
   LDP Weighs Clinical Development Infrastructure Utilizing Patient Registry(Apr.24)
   Council on Unapproved Drugs to Issue Development Requests Immediately In Cases of Unanimous Approval by Working Groups(Apr.24)
BUSINESS
   Astellas Sees 59% Rise in FY2014 Operating Profit(Apr.24)
   Strategia Therapeutics Starts PI/IIa Study of Anticancer Agent Licensed from Eisai in US(Apr.24)
   Sales Rep Survey – Part 3: Chugai, Takeda Raise Base Salaries, Reflecting “Social Trend”(Apr.24)
ORGANIZATION
   JPMA Preparing “Action Guidelines” to Ensure Greater Transparency(Apr.24)
   Expert Warns against Research-Driven Makers’ Foray into Indian Market(Apr.22)
   JPMA to Step Up Calls for Biowaivers Using IVIVC(Apr.21)
ACADEMIA
   Biometric Society of Japan to Establish Certification System for Biostatisticians(Apr.17)
   Study Group Recommends “Reference Groups,” Dose-Escalation Studies to Promote Development of Ultra-Orphan Drugs(Apr.08)
   Medical University Association to Strengthen Collaboration with Industry(Apr.03)

Commentary

Will Japanese Drug Makers Become More Discerning in Unearthing Seeds?

Lexicon

Annual NHI Drug Price Revisions:
毎年改定

The Column

The Truth about Recruiters

Archives

Strategia Therapeutics Starts PI/IIa Study of Anticancer Agent Licensed from Eisai in US(Apr.24)
Sales Rep Survey – Part 3: Chugai, Takeda Raise Base Salaries, Reflecting “Social Trend”(Apr.24)
Will 5,000 Contract Sales Reps Be Just a Way Station for a Higher Goal Beyond?(Apr.24)
Polyethylene Glycol Has Great Unmet Medical Need: Panel(Apr.23)
MHLW Official Jo Hints at Possible Move-Up of Generic Roadmap(Apr.23)

Most Read

1.
Sales Rep Survey - Part 1: Decreases in ...
2.
Baxter Files NDA for Advate Successor in...
2.
Merck KGaA, Pfizer Start Multinational P...
2.
Takeda Hooks Up with Prof. Yamanaka on i...
5.
Who Will Foot the Bill for Cost-Effectiv...

News Calendar